Sign up for email alert when new content gets added: Sign up
Background: Increasing antipsychotics have altered the course of schizophrenia. Few drugs have shown improvement in negative symptoms
and cognitive deficits, compounded by intolerable side effects. Lurasidone is a relatively new entrant in the field of schizophrenia in the Indian
context. This study evaluated the overall efficacy of Lurasidone across the whole spectrum of symptoms of schizophrenia and compared the degrees of
improvement in the positive and negative domains.
Methods: This is a longitudinal observational study. PANSS was administered at baseline, after 1 month, and after 3 months. A total of 57 patients,
diagnosed using ICD-10 criteria, were recruited from the psychiatry OPD of MVJ Medical College and Research Hospital. 7 patients dropped out due to
intolerability. The remaining was followed up. Statistical analysis of the data was done using the Statistical Package for Social Sciences Software (SPSS).Using appropriate statistical methods, dimensional comparisons were made using the central tendencies like means with S.D for Lurasidone before and after treatment.
Results: In the positive scale of PANSS, the mean reduction of positive score at the end of 4 weeks was 6.13, at the end of 3 months the mean positive
score was 10.900. Both scores were statistically significant. In the negative scale of PANSS, mean reduction of negative scores at the end of 4 weeks was 6.615, which were statistically significant; at the end of 3 months, the mean reduction on negative scores was 10.35 which were statistically significant.
Conclusion: The current study showed that Lurasidone has effect on both positive and negative symptoms of schizophrenia at week 4 and better efficacy
at week 12. Overall results show better response to positive symptoms. However a longer follow up would help us study the influence of Lurasidone
on the course of schizophrenia as well as response to individual domains and symptoms.